Competition Commission blocks Parkway's acquisition of Radlink-Asia

To prevent a healthcare monopoly.

The Competition Commission of Singapore (CCS) has blocked the proposed acquisition of Radlink-Asia by Parkway Holdings and Fortis Healthcare Singapore.

CCS reached its provisional decision to block the transaction after discovering that Parkway would become the only commercial supplier of radiopharmaceuticals in Singapore after the merger.

The CCS further noted that Parkway and RadLink are each other’s closest competitors in the provision of radiology and imaging services for private outpatients in Singapore, and the merged entity would have a “very substantial market share”.

“CCS’s market inquiries indicated that the merged entity would be able to restrict competition in the market for radiology and imaging services by controlling the supply, the prices and/or the range of radiopharmaceuticals available to its downstream competitors,” stated CCS in a release.